Drugs / QBECO SSI
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03472690 | Jun 2018 → Dec 2020 | Crohn disease | Qu Biologics Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02426372 | Jul 2015 → Dec 2016 | ulcerative colitis | Qu Biologics Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-02-10 | Qu Biologics Inc. | Results Qu Biologics’ Immunomodulator Clears Senescence qubiologics.com ↗
Qu’s QBECO immunomodulator substantially reduced the most widely used biomarker of cellular senescence in the liver of mice with fatty liver disease. |
| 2025-01-06 | Qu Biologics Inc. | Results Qu Biologics’ Immunomodulator Improves Fatty Liver Disease qubiologics.com ↗
In a series of studies at McMaster, Dr. Schertzer’s research group demonstrated that treatment with QBECO SSI resulted in a marked reduction in liver fat, inflammation, and fibrosis in fatty liver disease. |
| 2024-12-16 | Qu Biologics Inc. | Results Qu Biologics’ Site Specific Immunomodulator Enables CAR T-cell Cancer Efficacy in Solid Tumor qubiologics.com ↗
In this experimental study, scientists demonstrated that combining QBECO SSI with CAR T-cell therapy significantly improved survival rates compared to CAR T-cell therapy alone, achieving an impressive 80% survival rate after 31 days of treatment. |
| 2022-09-27 | Qu Biologics Inc. | Regulatory Qu Biologics to Launch Phase 2B Clinical Trial to Assess Reduction of Postoperative Immune Suppression and Disease Progression in Patients with Late-Stage Colorectal Cancer qubiologics.com ↗
it has received Health Canada clearance (No Objection Letter) and institutional-level ethics approval to proceed with a randomized placebo-controlled Phase II multicenter trial |
| 2021-07-13 | Qu Biologics Inc. | Results Qu Biologics’ Phase 2 RESTORE trial data presented at 2021 European Crohn’s and Colitis Congress qubiologics.com ↗
The RESTORE study, presented at ECCO 2021, demonstrated both symptom improvement/remission and endoscopic response. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-02-10 | Qu Biologics Inc. | Qu Biologics’ Immunomodulator Clears Senescence qubiologics.com ↗ |
| 2025-01-06 | Qu Biologics Inc. | Qu Biologics’ Immunomodulator Improves Fatty Liver Disease qubiologics.com ↗ |
| 2024-12-16 | Qu Biologics Inc. | Qu Biologics’ Site Specific Immunomodulator Enables CAR T-cell Cancer Efficacy in Solid Tumor qubiologics.com ↗ |
| 2022-09-27 | Qu Biologics Inc. | Qu Biologics to Launch Phase 2B Clinical Trial to Assess Reduction of Postoperative Immune Suppression and Disease Progression in Patients with Late-Stage Colorectal Cancer qubiologics.com ↗ |
| 2021-07-13 | Qu Biologics Inc. | Qu Biologics’ Phase 2 RESTORE trial data presented at 2021 European Crohn’s and Colitis Congress qubiologics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QBECO-SSI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03472690 ↗ |
| Route | Subcutaneous | “0.02 mL administered subcutaneously” NCT02426372 ↗ |